Molecular imaging developer Gamma Medica has initiated a campaign to spread awareness about breast tissue density and how molecular breast imaging (MBI) can serve as an effective adjunct to mammography for women with dense tissue.
With its Be Certain initiative, the company hopes to educate patients, physicians, breast surgeons, and radiologists about how molecular breast imaging can increase cancer detection rates when used as a supplemental screening tool to the traditional mammogram, Gamma Medica said.
